Elsevier

Respiratory Investigation

Volume 60, Issue 1, January 2022, Pages 158-161
Respiratory Investigation

Rapid Communication
Transient leukocytopenia following combination therapy for COVID-19

https://doi.org/10.1016/j.resinv.2021.09.007Get rights and content

Abstract

Background

Combination therapy with dexamethasone, remdesivir, and baricitinib has become a promising treatment for moderate or severe COVID-19; however, we have observed transient leukocytopenia in COVID-19 patients who received combination therapy.

Methods

Twelve consecutive COVID-19 patients treated with combination therapy were included in this retrospective analysis. Blood cell counts collected at the following three time points were analyzed: before the start of therapy (period 1), within 24 h of starting therapy (period 2), and within 48 h of period 2 (period 3).

Results

The leukocyte count significantly decreased in period 2 compared to period 1 and then significantly increased in period 3 without withdrawal of baricitinib. The neutrophil count transiently decreased in period 2 and recovered in period 3.

Conclusions

Clinicians should be aware of transient leukocytopenia in patients with COVID-19 during the early phase of combination therapy.

Keywords

COVID-19
Remdesivir
Baricitinib
Leukocytopenia

Cited by (0)

View Abstract